Compare Summit Therapeutics Inc (SMMT) vs Teucrium Soybean Fund (SOYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Teucrium Soybean Fund — how do they compare? Summit Therapeutics Inc trades at $17.59 (market cap $13.71B), while Teucrium Soybean Fund trades at $27.57 (market cap $43.52M). The key difference: Summit Therapeutics Inc is far larger — about 315× Teucrium Soybean Fund's market cap, and Teucrium Soybean Fund is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Teucrium Soybean Fund for 23 Days on average.
| SMMT | SOYB | |
|---|---|---|
Market Cap | $13.71B | $43.52M |
Volume | 6,173,057 | 32,585 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $26.38 | $28.14 |
52-Week Low | $12.43 | $21.55 |
Typical Hold Time | 16 Days | 23 Days |
Enterprise Value | $13.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
SOYB trades at $27.57, down slightly by 0.07% today, with a bullish technical signal driven by strong moving average alignment. Recent news highlights potential catalysts from U.S.-China trade talks and agricultural commodity trends. Key support and resistance are tightly clustered around $27 and $28, indicating a consolidation phase.
The outlook is cautiously optimistic due to positive technical momentum and geopolitical developments, but fundamental data is unavailable, limiting valuation clarity. Risks include trade negotiation outcomes and broader commodity market volatility, requiring careful monitoring of upcoming earnings and guidance for a complete investment picture.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Teucrium Soybean Fund
SOYB is a commodity ETF that provides exposure to the price of soybean futures. It utilizes a laddered strategy by investing in several benchmark futures contracts to reduce the impact of roll costs and contango in the agricultural market.
Read more on SOYB →
